Key result
VEGF-targeting therapies, including bevacizumab, sunitinib, and sorafenib, are associated with cardiovascular toxicities that require baseline risk assessment and strict monitoring during treatment.
Why the study?
What are the cardiovascular toxicities associated with VEGF-targeting therapies and how should they be managed?
What are the cardiovascular toxicities associated with VEGF-targeting therapies and how should they be managed?
VEGF-targeting therapies are associated with cardiovascular toxicities that require careful baseline assessment and strict monitoring for early detection and management.
May support CV monitoring with VEGF inhibitors; leaves open need for prospective trials to guide protocols.
Treatment with the angiogenesis inhibitors bevacizumab, sunitinib, and sorafenib as single agents or in combination with conventional chemotherapy is becoming a cornerstone of modern anticancer therapy. However, the potential toxicity of these drugs, mainly to the cardiovascular system, is still being investigated. Patient assessment at baseline, of crucial importance in candidates for treatment, involves the evaluation of risk factors and screening for past or present cardiovascular disease. Strict monitoring of treatment-related adverse effects must be conducted in order to allow the early detection of cardiovascular toxicities and their prompt medication. In the present paper, the most frequent cardiovascular toxicities and their underlying mechanisms are investigated, with a view to providing indications for effective patient management.
No takes yet. Share an insight, caveat, or question.
Girardi et al. (2010) conducted a review in Cancer (candidates for VEGF-targeting therapies). VEGF-targeting therapies (bevacizumab, sunitinib, sorafenib) was evaluated on Cardiovascular toxicities. VEGF-targeting therapies, including bevacizumab, sunitinib, and sorafenib, are associated with cardiovascular toxicities that require baseline risk assessment and strict monitoring during treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: